Highlights and Quick Summary
- Annual ROE for 2021 was 291.59% (a -115.14% decrease from previous year)
- Annual ROE for 2020 was -1925.37% (a 673.43% increase from previous year)
- Annual ROE for 2019 was -248.94% (a 63.5% increase from previous year)
- Twelve month ROE ending September 30, 2022 was 99.23% (a -24.43% decrease compared to previous quarter)
- Twelve month trailing ROE decreased by -65.97% year-over-year
Trailing ROE for the last four month:
| 30 Sep '22 | 30 Jun '22 | 31 Mar '22 | 31 Dec '21 |
|---|---|---|---|
| 99.23% | 131.31% | 162.18% | 291.59% |
Visit stockrow.com/BCRX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical ROE of BioCryst Pharmaceuticals, Inc.
Most recent ROEof BCRX including historical data for past 10 years.Interactive Chart of ROE of BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. ROE for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | – | – | – | – | 291.59% |
| 2020 | – | – | – | – | -1925.37% |
| 2019 | – | – | – | – | -248.94% |
| 2018 | – | – | – | – | -152.26% |
| 2017 | – | – | – | – | -154.16% |
| 2016 | – | – | – | – | -223.7% |
| 2015 | – | – | – | – | -69.75% |
| 2014 | – | – | – | – | -121.3% |
| 2013 | – | – | – | – | 3811.14% |
| 2012 | – | – | – | – | -544.61% |
Business Profile of BioCryst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology